Resolve Therapeutics LLC – Trademark Portfolio
Entity Type: 16
Resolve Therapeutics LLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ORYN THERAPEUTICS. The owner is based in Miami, FL.
1951 NW 7th Ave., Suite 300
Miami, FL 33136
Showing of trademarks Trademarks
Trademark Classifications
Resolve Therapeutics LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Resolve Therapeutics LLC have?
Resolve Therapeutics LLC has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 1 cancelled.
What trademark classes does Resolve Therapeutics LLC file in?
Resolve Therapeutics LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Resolve Therapeutics LLC's most well-known trademarks?
Resolve Therapeutics LLC's registered trademark portfolio includes well-known marks such as ORYN THERAPEUTICS. These are among 1 currently registered trademark in the portfolio.
What is Resolve Therapeutics LLC's trademark registration success rate?
Resolve Therapeutics LLC has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.